Get started
Author

Vadim Viktorovich Kozlov

Observed names: V V Kozlov, V. Kozlov, V. V. Kozlov, V.V. Kozlov, V.V. Коzlov, Vadim Kozlov, Vadim V. Kozlov
Observed institutions: Memorial Sloan Kettering Cancer Center, Novosibirsk State Medical University, Novosibirsk State University, Seoul National University Hospital, Federal Almazov North-West Medical Research Centre, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Federal Research Center of Fundamental and Translational Medicine, P.A. Hertzen Moscow Oncology Research Institute, Institute of Molecular Biology and Biophysics, Yonsei University Health System, Institute of Molecular Biology and Biophysics
ORCID: 0000-0003-3211-5139
Observed ORCID: 0000-0003-3211-5139
OpenAlex ID: A5085103841
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
2021 · Robert Motzer, Boris Alekseev, et al. · New England Journal of Medicine · 1,877
PDF
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
2025 · Yelena Y. Janjigian, Salah-Eddin Al-Batran, et al. · CRC Press eBooks · 428
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Robert J. Motzer, Camillo Porta, et al. · Journal of Clinical Oncology · 222
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
2021 · Renato D. Lopes, Celestia S. Higano, et al. · Circulation · 166
Variety of RNAs in Peripheral Blood Cells, Plasma, and Plasma Fractions
2017 · Anna V. Savelyeva, Elena V. Kuligina, et al. · BioMed Research International · 117
PDF
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
2022 · Jonathan E. Rosenberg, Se Hoon Park, et al. · Journal of Clinical Oncology · 59
PDF
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
2022 · Martin J. Edelman, Mikhail Dvorkin, et al. · Lung Cancer · 51
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
2023 · Viktor Grünwald, Thomas Powles, et al. · European Urology Oncology · 39
Increased expression of miR-155 and miR-222 is associated with lymph node positive status
2017 · Vladimir Chernyy, Vladimir Pustylnyak, et al. · Journal of Cancer · 33
Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
2021 · Viktor Grünwald, Thomas Powles, et al. · Journal of Clinical Oncology · 22
New Insight into the Role of AhR in Lung Carcinogenesis
2022 · Dinara A. Akhmetova, Vadim V. Kozlov, et al. · Biochemistry (Moscow) · 19
PDF
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).
2025 · Yelena Y. Janjigian, Hanneke W.M. Van Laarhoven, et al. · Journal of Clinical Oncology · 18
PDF
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
2020 · Martin Edelman, Mikhail Dvorkin, et al. · Journal of Clinical Oncology · 15
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
2025 · K. Laktionov, A. Smolin, et al. · European Journal of Cancer · 12
Mycoplasma hyorhinis reduces sensitivity of human lung carcinoma cells to Nutlin-3 and promotes their malignant phenotype
2018 · Uljana A. Boyarskikh, Alexandra S. Shadrina, et al. · Journal of Cancer Research and Clinical Oncology · 11
Use of antigen‑primed dendritic cells for inducing antitumor immune responses in�vitro in patients with non‑small cell lung cancer
2017 · Irina Obleukhova, Nataliya Kiryishina, et al. · Oncology Letters · 9
PDF
Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
2023 · Igor V. Samoylenko, Lev V. Demidov, et al. · Journal of Modern Oncology · 7
PDF
Search of MicroRNAs Regulating the Receptor Status of Breast Cancer In Silico and Experimental Confirmation of Their Expression in Tumors
2017 · V. S. Chernyi, P. V. Tarasova, et al. · Bulletin of Experimental Biology and Medicine · 7
Tumor suppressor PTEN regulation by tobacco smoke in lung squamous-cell carcinoma based on bioinformatics analysis
2023 · Vladimir O. Pustylnyak, Efim Y. Alekseenok, et al. · Heliyon · 6
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
2025 · Lev Demidov, Igor Samoylenko, et al. · European Journal of Cancer · 5
Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues
2019 · Igor P. Oscorbin, Alexandra S. Shadrina, et al. · Pathology & Oncology Research · 5
Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial
2025 · Lev Demidov, Igor Samoylenko, et al. · Cancer Research · 4
Dendritic cells transfected with a polyepitope DNA construct stimulate an antitumor cytotoxic response in various tumors
2022 · Vasily Kurilin, Ekaterina Kulikova, et al. · Molecular and Clinical Oncology · 4
PDF
Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung Cancer
2024 · Elena G. Ufimtseva, Margarita S. Gileva, et al. · Cancers · 3
PDF
Expression of AhR-regulated miRNAs in non-small cell lung cancer in smokers and never smokers
2024 · T.S. Kalinina, V.V. Kononchuk, et al. · Biomeditsinskaya Khimiya · 3
PDF
Works count: 72
Citation count: 3,162
H-index: 13
I10-index: 15
Year
Topic
Type